Summit Therapeutics (SMMT) Expands its Phase 3 Trials for Ivonescimab

​Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the Best Growth Stocks Under $25 to Buy Right Now. On October 17, Summit Therapeutics Inc. (NASDAQ:SMMT) announced the expansion of its Phase 3 clinical development program called HARMONi-GI3, for its candidate Ivonescimab. ​Ivonescimab is a novel biospecific antibody that combines with chemotherapy in patients with unresectable metastatic colorectal cancer. The phase 3 trials will compare ivonescimab plus chemotherapy with bevacizumab plus chemotherapy as ...